POINT Biopharma Global Inc. , a company engaged in the discovery, development, and global access to life-changing radiopharmaceuticals, has affirmed that a recent reactor shutdown in Europe and current geopolitical events concerning Russia and Ukraine have not impacted the Company’s trial timelines or the Company’s 2022 business outlook.

To read more please visit:

POINT Biopharma Confirms No Delays to SPLASH Trial Due to Recent Global Lutetium Supply Interruption

Source: POINT